Abstract | PURPOSE: METHODS: This was a bicentered retrospective case series performed at institutional referral centers. Seventy-two eyes of 37 patients who had intravitreal injections of either bevacizumab or ranibizumab as the primary treatment for Type 1 ROP were included. Outcomes' measures included regression and recurrence of ROP, the surgical complications, and refractive errors at a corrected age of 1 year. RESULTS: CONCLUSION:
|
Authors | San-Ni Chen, Iebin Lian, Ya-Chi Hwang, Yi-Hsing Chen, Yao-Chung Chang, Kun-Hsien Lee, Chih-Chun Chuang, Wei-Chi Wu |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 35
Issue 4
Pg. 667-74
(Apr 2015)
ISSN: 1539-2864 [Electronic] United States |
PMID | 25462435
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Bevacizumab
- Ranibizumab
|
Topics |
- Angiogenesis Inhibitors
(therapeutic use)
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Axial Length, Eye
- Bevacizumab
- Female
- Gestational Age
- Humans
- Infant
- Intravitreal Injections
- Male
- Ranibizumab
- Recurrence
- Refractive Errors
(diagnosis)
- Retinal Neovascularization
(drug therapy)
- Retinopathy of Prematurity
(classification, diagnosis, drug therapy)
- Retrospective Studies
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
|